US5227537A - Method for the production of 6,12-dihydro-6-hydroxy-cannabidiol and the use thereof for the production of trans-delta-9-tetrahydrocannabinol - Google Patents

Method for the production of 6,12-dihydro-6-hydroxy-cannabidiol and the use thereof for the production of trans-delta-9-tetrahydrocannabinol Download PDF

Info

Publication number
US5227537A
US5227537A US07/818,040 US81804092A US5227537A US 5227537 A US5227537 A US 5227537A US 81804092 A US81804092 A US 81804092A US 5227537 A US5227537 A US 5227537A
Authority
US
United States
Prior art keywords
cannabidiol
hydroxy
dihydro
acid
catalyst
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US07/818,040
Other languages
English (en)
Inventor
Peter Stoss
Peter Merrath
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Heinrich Mack Nachf GmbH and Co
Original Assignee
Heinrich Mack Nachf GmbH and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heinrich Mack Nachf GmbH and Co filed Critical Heinrich Mack Nachf GmbH and Co
Assigned to HEINRICH MACK NACHF. reassignment HEINRICH MACK NACHF. ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: MERRATH, PETER, STOSS, PETER
Application granted granted Critical
Publication of US5227537A publication Critical patent/US5227537A/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/23—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
    • C07C37/11—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by reactions increasing the number of carbon atoms
    • C07C37/14—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by reactions increasing the number of carbon atoms by addition reactions, i.e. reactions involving at least one carbon-to-carbon unsaturated bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Definitions

  • Cannabinoid compounds are components which can be isolated from Cannabis spp. Due to its physiological activity trans-delta-9-tetrahydrocannabinol ( ⁇ 9 -THC) is of substantial significance. This compound is also referred to as 6a,7,8,10a-tetradydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol.
  • the psychotropic but non-habit forming effects mean that this compound is of interest as pharmaceutical component.
  • One object of the present invention is therefore to provide a method for the production of trans-delta-9-tetrahydrocannabinol both with a sufficient purity and also on an industrial scale.
  • trans-delta-9-tetrahydrocannabinol is produced as an intermediate, which may be readily purified by crystallization. This intermediate is then converted by ring condensation to the desired delta-9-THC.
  • the first step is to produce the intermediate 6,12-dihydro-6-hydroxy-cannabidiol which may also be termed
  • the starting materials are the readily available olivetol (formula II) and cis-p-menth-2-ene-1,8-diol (formula III).
  • the reaction is performed in a suitable solvent, aromatic hydrocarbons such as benzene and toluene, halogenated hydrocarbons such as methylene chloride, chloroform, dichloroethane and trichloroethane, ethers such as diethylether, diisopropylether and tetrahydrofuran having proved to be suitable.
  • aromatic hydrocarbons such as benzene and toluene
  • halogenated hydrocarbons such as methylene chloride, chloroform, dichloroethane and trichloroethane
  • ethers such as diethylether, diisopropylether and tetrahydrofuran having proved to be suitable.
  • mixtures of the said solvents are possible to use mixtures of the said solvents.
  • Toluene, benzene, methylene chloride and chloroform are the preferred solvents for use in the method of the invention.
  • the reaction in accordance with the invention is performed in the presence of a suitable catalyst, proton acids such as for instance haloid acids, sulfuric acid, phosphoric acid, perchloric acid, organic sulfonic acids, such as for instance methanesulfonic acid and p-toluenesulfonic acid, carboxylic acids, such as for instance oxalic acid, trifluoroacetic acid and other Lewis acids, such for instance boron trifluoride, ferric chloride, zinc chloride, zinc bromide, stannic chloride, titanium chloride or iodine having proved to be suitable.
  • a suitable catalyst proton acids such as for instance haloid acids, sulfuric acid, phosphoric acid, perchloric acid, organic sulfonic acids, such as for instance methanesulfonic acid and p-toluenesulfonic acid, carboxylic acids, such as for instance oxalic acid, trifluoroacetic acid and other Lewis acids, such for instance boro
  • hydrochloric acid and p-toluenesulfonic acid are used in accordance with the invention.
  • the method may be performed at temperatures between approximately -30° C. and +50° C., temperatures between 0° C. and 20° C. being preferred.
  • reaction times are dependent on the solvent, the catalyst used and the reaction temperature. In fact it is possible to use reaction times between a few minutes and several hours.
  • the intermediate product produced may then be readily further purified by recrystallization.
  • the use of petroleum ether has turned out to be suitable for the recrystallization.
  • Ring condensation may be used to produce the trans-delta-9-tetrahydrocannabinol ( ⁇ 9 -THC) from 6,12-dihydro-6-hydroxy-cannabidol.
  • This reaction is performed in a suitable solvent with the use of suitable catalysts and water binding substances.
  • the solvent is in the form of a hydrocarbon, as for instance hexane, heptane, cyclohexane, petroleum ether, aromatic hydrocarbons, such as for instance benzene, toluene, chorinated hydrocarbons, such as for instance methylene chloride, chloroform and dichloroethane.
  • methylene chloride and chloroform are used.
  • mixtures of the solvents may be used.
  • Lewis acids such as for instance zinc chloride, zinc bromide, boron trifluoride, ferric chloride, stannic chloride, titanium chloride or iodine are used, zinc chloride and zinc bromide having proved to be more particularly suitable.
  • Water binding substances such as neutral substances as for instance magnesium sulfate, sodium sulfate, calcium sulfate or molecular sieves may be used, the last-named having proved more particularly suitable.
  • the reaction is performed at a temperature between approximately -20° C. and the boiling point of the corresponding solvent.
  • reaction times are dependent on the catalyst, the solvent, the water binding substance and the reaction temperature. Dependent on the selected conditions times from a few minutes to several days are required.
  • the petroleum ether phase was then run into a silica gel column (approximately 500 g of silica gel) and eluted with a mixture of petroleum ether (50/70) and diisopropylether (2:1). The eluate was reduced in volume under vacuum and the residue (approximately 102 g) was recrystallized from 600 ml of petroleum ether (50/70). 77 g of the desired product were obtained.
  • the characteristic data of the 6,12-dihydro-6-hydroxy-cannabidiol were as follows:
  • UV spectrum (UV) ⁇ max (ethanol 95%) 275 nm ( ⁇ 1024) ⁇ max (ethanol 95%) 281 nm ( ⁇ 987)
  • Infrared spectrum (IR, KBr pellet) [cm] -1 3392, 2956, 2930, 2859, 1630, 1582, 1446, 1379, 1369, 1335, 1308, 1231, 1202, 1186, 1158, 1076, 1046, 1028.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
US07/818,040 1991-01-09 1992-01-08 Method for the production of 6,12-dihydro-6-hydroxy-cannabidiol and the use thereof for the production of trans-delta-9-tetrahydrocannabinol Expired - Fee Related US5227537A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4100441 1991-01-09
DE4100441A DE4100441A1 (de) 1991-01-09 1991-01-09 Verfahren zur herstellung von 6,12-dihydro-6-hydroxy-cannabidiol und dessen verwendung zur herstellung von trans-delta-9-tetrahydrocannabinol

Publications (1)

Publication Number Publication Date
US5227537A true US5227537A (en) 1993-07-13

Family

ID=6422735

Family Applications (1)

Application Number Title Priority Date Filing Date
US07/818,040 Expired - Fee Related US5227537A (en) 1991-01-09 1992-01-08 Method for the production of 6,12-dihydro-6-hydroxy-cannabidiol and the use thereof for the production of trans-delta-9-tetrahydrocannabinol

Country Status (7)

Country Link
US (1) US5227537A (de)
EP (1) EP0494665B1 (de)
JP (1) JP2637659B2 (de)
AT (1) ATE121066T1 (de)
DE (2) DE4100441A1 (de)
DK (1) DK0494665T3 (de)
ES (1) ES2071351T3 (de)

Cited By (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274635B1 (en) 1999-03-22 2001-08-14 Immugen Pharmaceuticals Inc. Alkylated resorcinol derivatives for the treatment of immune diseases
WO2002062782A1 (de) * 2001-02-09 2002-08-15 Christian Steup Verfahren zur herstellung von dronabinol
US6566560B2 (en) 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
US6630507B1 (en) 1998-04-21 2003-10-07 The United States Of America As Represented By The Department Of Health And Human Services Cannabinoids as antioxidants and neuroprotectants
US20030232101A1 (en) * 2002-03-18 2003-12-18 Immugen Pharmaceuticals, Inc. Topical formulations of resorcinols and cannibinoids and methods of use
US20040033280A1 (en) * 2002-08-14 2004-02-19 Whittle Brian A. Extraction of pharmaceutically active components from plant materials
US20040049059A1 (en) * 2000-10-17 2004-03-11 Adam Mueller Method for producing an extract from cannabis plant matter, containing a tetrahydrocannabinol and a cannabidiol and cannabis extracts
US20040138315A1 (en) * 2000-09-28 2004-07-15 Immugen Pharmaceuticals, Inc. Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation
US20040210076A1 (en) * 2001-05-25 2004-10-21 Michael Casner Uncatalysed addition reactions
US20040236153A1 (en) * 2001-08-15 2004-11-25 George Kunos Novel vasoconstrictor cannabinoid analogs
US20040242870A1 (en) * 2000-09-28 2004-12-02 Immugen Pharmaceuticals, Inc. Antiviral methods and compounds
US20040249174A1 (en) * 2001-05-25 2004-12-09 Silverberg Lee Jonathan Synthesis of cannabinoids
WO2005100333A1 (en) * 2004-04-07 2005-10-27 Cedarburg Pharmaceuticals, Inc. Methods and intermediates for the synthesis of delta-9 tetrahydrocannabinol
US20060194761A1 (en) * 2003-04-10 2006-08-31 Hong Gu Olivetol-cyclodextrin complexes and regio-selective process for preparing delta 9-tetrahydrocannabinol
US20070072939A1 (en) * 2005-06-16 2007-03-29 Euro-Celtique, S.A. Cannabinoid active pharmaceutical ingredient for improved dosage forms
US20070093665A1 (en) * 2005-09-29 2007-04-26 Amr Technology, Inc. Process for production of delta-9- tetrahydrocannabinol
US20070282222A1 (en) * 2006-06-01 2007-12-06 Daniel Larkin Sexually transmitted infection sampling device
US7323576B2 (en) 2004-10-01 2008-01-29 Alphora Research Inc. Synthetic route to dronabinol
US20090298930A1 (en) * 2004-11-22 2009-12-03 Gutman Arie L Methods For Purifying Trans-(-) Delta9-Tetrahydrocannabinol And Trans-(+)-Delta9-Tetrahydrocannabinol
AU2008200935B2 (en) * 2001-02-05 2010-02-04 Thc Pharm The Health Concept Gmbh Method for the Production of Dronabinol
WO2016014454A1 (en) 2014-07-21 2016-01-28 Pharmaceutical Productions, Inc. Solid dosage form composition for buccal or sublingual administration of cannabinoids
WO2017011210A1 (en) 2015-07-10 2017-01-19 Noramco, Inc. Process for the production of cannabidiol and delta-9-tetrahydrocannabinol
WO2018176055A2 (en) 2017-03-24 2018-09-27 Trait Biosciences, Inc. High level in vivo biosynthesis and isolation of water-soluble cannabinoids in plant systems
WO2020014200A1 (en) 2018-07-09 2020-01-16 Volker Berl Stabilized formulations of cannabinoid compositions
WO2020031179A1 (en) 2018-08-06 2020-02-13 Beetlebung Pharma Ltd. Methods for synthesis of cannabinoid compounds
WO2020051371A2 (en) 2018-09-05 2020-03-12 Noramco, Inc. Cannabidiol compositions having modified cannabinoid profiles
US10640482B2 (en) 2017-07-21 2020-05-05 University Of South Florida Synthesis of cannabinoids
WO2020099942A1 (en) * 2018-11-14 2020-05-22 Embio Limited Process and compounds for preparation of cannabinoids
EP3686281A1 (de) 2018-01-24 2020-07-29 Trait Biosciences, Inc. Systeme und verfahren zur verbesserung der trichombildung und dichte bei cannabis
EP3730145A1 (de) 2017-07-11 2020-10-28 Trait Biosciences, Inc. Erzeugung von wasserlöslichen cannabinoid-verbindungen in hefe- und pflanzenzellsuspensionskulturen und stoffzusammensetzungen
WO2020233502A1 (zh) 2019-05-17 2020-11-26 上海特化医药科技有限公司 大麻二酚类化合物的制备方法
WO2021019536A1 (en) 2019-07-30 2021-02-04 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Methods of controlling cannabinoid synthesis in plants or cells and plants and cells produced thereby
WO2021102428A1 (en) 2019-11-21 2021-05-27 Shinkei Therapeutics, Inc. Cannabidiol and/or cobicistat combination drug therapy
US11242328B1 (en) * 2021-02-25 2022-02-08 Acid Neutral Alkaline Laboratory Heterogeneous catalyst and method for preparation of aromatic tricyclic pyrans
US11352337B1 (en) * 2021-06-02 2022-06-07 Acid Neutral Alkaline Laboratory Zeolite catalyst and method for preparation of aromatic tricyclic pyrans
WO2022115921A1 (en) 2020-12-04 2022-06-09 Cymra Life Sciences Limited Antiinflammatory compositions comprising cannabidiol, delta-9- tetrahydrocannabinol and linalool
EP4124336A1 (de) 2021-07-30 2023-02-01 Cannamedical Pharma GmbH Transmukosales pflaster mit einem cannabinoid und/oder einem opioid
US12029719B2 (en) 2021-04-16 2024-07-09 Allen Morgan Compounds comprising cannabinoids and other natural ingredients for alieving premenstrual, menstrual and menopausal symptoms
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
WO2024160792A1 (en) 2023-01-30 2024-08-08 Cannamedical Pharma Gmbh Improved transmucosal patch comprising a cannabinoid and/or an opioid
US12103950B2 (en) 2022-01-27 2024-10-01 University Of Connecticut Transgenic plants that overexpress a R2R3-MYB transcription factor gene and methods for producing the same
WO2024231543A1 (en) 2023-05-10 2024-11-14 Gb Lab Cannabinoid derivatives for treating autism spectrum disorder
US12391711B2 (en) 2020-01-08 2025-08-19 Chengdu Baiyu Pharmaceutical Co., Ltd. Tetrahydrocannabinol derivatives, preparation method thereof and use thereof
US12545694B2 (en) 2020-01-08 2026-02-10 Chengdu Baiyu Pharmaceutical Co., Ltd. Cannabidiol derivatives, preparation method thereof and use thereof

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342971A (en) * 1992-12-29 1994-08-30 The Australian National University Process for the preparation of dibenzo[b,d]pyrans
MXPA05001621A (es) * 2002-08-14 2005-08-19 Gw Pharma Ltd Extraccion de cannabinoides farmaceuticamente activos de materiales vegetales.
US7169942B2 (en) * 2003-05-20 2007-01-30 University Of Tennessee Research Foundation Cannabinoid derivatives, methods of making, and use thereof
DE102005028937B4 (de) * 2005-06-22 2009-07-23 Bionorica Ag Verfahren zur Herstellung von Dronabinol
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
US11202771B2 (en) 2018-01-31 2021-12-21 Treehouse Biotech, Inc. Hemp powder
EP3864000A4 (de) 2018-10-10 2022-08-10 Treehouse Biosciences, Inc. Synthese von cannabigerol
CN114096241A (zh) 2019-05-16 2022-02-25 技术研究及发展基金有限公司 大麻素及其用途
EP4089084A4 (de) * 2020-01-08 2024-03-13 Chengdu Baiyu Pharmaceutical Co., Ltd. Cannabidiolderivat, verfahren zu seiner herstellung und medizinische verwendung davon
WO2022101917A1 (en) * 2020-11-15 2022-05-19 Technion Research And Development Foundation Limited Cannabinoids, pharmaceutical compositions comprising same and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3656906A (en) * 1970-04-13 1972-04-18 Little Inc A Method for detecting and quantitating the presence of cannabinoids and analogs thereof in biological materials and resulting products

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4116979A (en) 1975-06-23 1978-09-26 Sheehan Institute For Research, Inc. Process for the preparation of (-)-6a,10a-trans-6a,7,8,10a-tetrahydrodibenzo[b,d]-pyrans
HU194858B (en) * 1982-12-03 1988-03-28 Chinoin Gyogyszer Es Vegyeszet Process for producing dibenzo/b,d/pirane derivatives and pharmaceutical compositions containing them
US4758597A (en) * 1987-05-15 1988-07-19 University Patents, Inc. Carenadiol and derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3656906A (en) * 1970-04-13 1972-04-18 Little Inc A Method for detecting and quantitating the presence of cannabinoids and analogs thereof in biological materials and resulting products

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Garrett et al., Chemical Abstracts vol. 88 (No. 22); p. 158340n (1978). *
Stoss et al, Chemical Abstracts, vol. 115 (No. 17) p. 183602h (1991). *
Tetrahedron Letters No. 8, pp. 681 684 (1979) Hendrick et al., Hashish:Synthesis of . . . . *
Tetrahedron Letters No. 8, pp. 681-684 (1979) Hendrick et al., "Hashish:Synthesis of . . . ".

Cited By (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630507B1 (en) 1998-04-21 2003-10-07 The United States Of America As Represented By The Department Of Health And Human Services Cannabinoids as antioxidants and neuroprotectants
US6274635B1 (en) 1999-03-22 2001-08-14 Immugen Pharmaceuticals Inc. Alkylated resorcinol derivatives for the treatment of immune diseases
US7105685B2 (en) 1999-03-22 2006-09-12 Travis Craig R Cannabinol derivatives
US6566560B2 (en) 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
US20040138315A1 (en) * 2000-09-28 2004-07-15 Immugen Pharmaceuticals, Inc. Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation
US20040242870A1 (en) * 2000-09-28 2004-12-02 Immugen Pharmaceuticals, Inc. Antiviral methods and compounds
US10870632B2 (en) 2000-10-17 2020-12-22 Bionorica Ethics Gmbh Process for producing an extract containing tetrahydrocannabinol and cannabidiol from cannabis plant material, and cannabis extracts
US8895078B2 (en) 2000-10-17 2014-11-25 Bionorica Ethics Gmbh Method for producing an extract from cannabis plant matter, containing a tetrahydrocannabinol and a cannabidiol and cannabis extracts
US20040049059A1 (en) * 2000-10-17 2004-03-11 Adam Mueller Method for producing an extract from cannabis plant matter, containing a tetrahydrocannabinol and a cannabidiol and cannabis extracts
USRE49434E1 (en) 2000-10-17 2023-02-28 Canopy Growth Corporation Process for producing an extract containing tetrahydrocannabinol and cannabidiol from cannabis plant material, and cannabis extracts
AU2008200935B2 (en) * 2001-02-05 2010-02-04 Thc Pharm The Health Concept Gmbh Method for the Production of Dronabinol
DE10106024A1 (de) * 2001-02-09 2002-08-22 Thc Pharm Gmbh Verfahren zur Herstellung von Dronabinol
DE10106024B4 (de) * 2001-02-09 2004-10-14 Thc Pharm Gmbh Verfahren zur Herstellung von Dronabinol
WO2002062782A1 (de) * 2001-02-09 2002-08-15 Christian Steup Verfahren zur herstellung von dronabinol
US20070123719A1 (en) * 2001-05-25 2007-05-31 Johnson Matthey Public Limited Company Synthesis of cannabinoids
US20040210076A1 (en) * 2001-05-25 2004-10-21 Michael Casner Uncatalysed addition reactions
US6867335B2 (en) 2001-05-25 2005-03-15 Johnson Matthey Public Limited Company Uncatalysed addition reactions
US7186850B2 (en) 2001-05-25 2007-03-06 Johnson Matthey Public Limited Company Synthesis of cannabinoids
US20040249174A1 (en) * 2001-05-25 2004-12-09 Silverberg Lee Jonathan Synthesis of cannabinoids
US20040236153A1 (en) * 2001-08-15 2004-11-25 George Kunos Novel vasoconstrictor cannabinoid analogs
US7109245B2 (en) 2001-08-15 2006-09-19 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Vasoconstrictor cannabinoid analogs
US20030232101A1 (en) * 2002-03-18 2003-12-18 Immugen Pharmaceuticals, Inc. Topical formulations of resorcinols and cannibinoids and methods of use
US7344736B2 (en) 2002-08-14 2008-03-18 Gw Pharma Limited Extraction of pharmaceutically active components from plant materials
US20080167483A1 (en) * 2002-08-14 2008-07-10 Gw Pharma Limited extraction of pharmaceutically active components from plant materials
US20040033280A1 (en) * 2002-08-14 2004-02-19 Whittle Brian A. Extraction of pharmaceutically active components from plant materials
US20060194761A1 (en) * 2003-04-10 2006-08-31 Hong Gu Olivetol-cyclodextrin complexes and regio-selective process for preparing delta 9-tetrahydrocannabinol
WO2005100333A1 (en) * 2004-04-07 2005-10-27 Cedarburg Pharmaceuticals, Inc. Methods and intermediates for the synthesis of delta-9 tetrahydrocannabinol
US20070287843A1 (en) * 2004-04-07 2007-12-13 Cabaj John E Methods and Intermediates for the Synthesis of Delta-9 Tetrahydrocannabinol
US7323576B2 (en) 2004-10-01 2008-01-29 Alphora Research Inc. Synthetic route to dronabinol
US9278083B2 (en) 2004-11-22 2016-03-08 Svc Pharma Lp Methods for purifying trans-(−)-Δ9-tetrahydrocannabinol and trans-(+)-Δ9-tetrahydrocannabinol
US8383842B2 (en) 2004-11-22 2013-02-26 Purdue Pharma L.P. Methods for purifying trans-(−)-Δ9-tetrahydrocannabinol and trans-(+)-Δ9-tetrahydrocannabinol
US9744151B2 (en) 2004-11-22 2017-08-29 Svc Pharma Lp Methods for purifying trans-(−)-Δ9-tetrahydrocannabinol and trans-(+)-Δ9-tetrahydrocannabinol
US9675581B2 (en) 2004-11-22 2017-06-13 Svc Pharma Lp Methods for purifying trans-(−)-Δ9-tetrahydrocannabinol and trans- (+)-Δ9-tetrahydrocannabinol
US8937097B2 (en) 2004-11-22 2015-01-20 Purdue Pharma L.P. Methods for purifying trans-(−)-Δ9-tetrahydrocannabinol and trans-(+)-Δ9-tetrahydrocannabinol
US20090298930A1 (en) * 2004-11-22 2009-12-03 Gutman Arie L Methods For Purifying Trans-(-) Delta9-Tetrahydrocannabinol And Trans-(+)-Delta9-Tetrahydrocannabinol
EP2279735A2 (de) 2005-06-16 2011-02-02 Euro-Celtique S.A. Zusammensetzungen mit kristallinem trans-(+/-)-delta-9-tetrahydrocannabinol
US20070072939A1 (en) * 2005-06-16 2007-03-29 Euro-Celtique, S.A. Cannabinoid active pharmaceutical ingredient for improved dosage forms
EP2263667A2 (de) 2005-06-16 2010-12-22 Euro-Celtique S.A. Zusammensetzungen mit kristallinem trans-(+/-)-delta-9-tetrahydrocannabinol
US8106244B2 (en) 2005-09-29 2012-01-31 Albany Molecular Research, Inc. Process for production of delta-9-tetrahydrocannabinol
US20070093665A1 (en) * 2005-09-29 2007-04-26 Amr Technology, Inc. Process for production of delta-9- tetrahydrocannabinol
US20100069651A1 (en) * 2005-09-29 2010-03-18 Albany Molecular Research, Inc. Process for production of delta-9-tetrahydrocannabinol
US7674922B2 (en) 2005-09-29 2010-03-09 Albany Molecular Research, Inc. Process for production of delta-9-tetrahydrocannabinol
US20070282222A1 (en) * 2006-06-01 2007-12-06 Daniel Larkin Sexually transmitted infection sampling device
WO2016014454A1 (en) 2014-07-21 2016-01-28 Pharmaceutical Productions, Inc. Solid dosage form composition for buccal or sublingual administration of cannabinoids
US11077086B2 (en) 2014-07-21 2021-08-03 Pharmaceutical Productions, Inc. Solid dosage form composition for buccal or sublingual administration of cannabinoids
WO2017011210A1 (en) 2015-07-10 2017-01-19 Noramco, Inc. Process for the production of cannabidiol and delta-9-tetrahydrocannabinol
US10059683B2 (en) 2015-07-10 2018-08-28 Noramco, Inc. Process for the production of cannabidiol and delta-9-tetrahydrocannabinol
EP3722276A1 (de) 2015-07-10 2020-10-14 Purisys LLC Verfahren zur herstellung von cannabidiol und gereinigtem cannabidiol
US10844035B2 (en) 2015-07-10 2020-11-24 Purisys Llc Process for the production of cannabidiol and delta-9-tetrahydrocannabinol
US11773402B2 (en) 2017-03-24 2023-10-03 Trait Biosciences Inc. High level in vivo biosynthesis and isolation of water-soluble cannabinoids in stably transformed plant systems
WO2018176055A2 (en) 2017-03-24 2018-09-27 Trait Biosciences, Inc. High level in vivo biosynthesis and isolation of water-soluble cannabinoids in plant systems
US11447788B2 (en) 2017-03-24 2022-09-20 Trait Biosceinces, Inc. System, methods, and compositions for high-level production of water-soluble cannabinoids in a plant cell culture
US11352634B2 (en) 2017-03-24 2022-06-07 Trait Biosciences, Inc. Methods for increasing cannabinoid production in cannabis plants
US11466281B2 (en) 2017-07-11 2022-10-11 Trait Biosciences Inc. Generation of water-soluble cannabinoid compounds in yeast and plant cell suspension cultures and compositions of matter
EP3730145A1 (de) 2017-07-11 2020-10-28 Trait Biosciences, Inc. Erzeugung von wasserlöslichen cannabinoid-verbindungen in hefe- und pflanzenzellsuspensionskulturen und stoffzusammensetzungen
US10640482B2 (en) 2017-07-21 2020-05-05 University Of South Florida Synthesis of cannabinoids
EP3686281A1 (de) 2018-01-24 2020-07-29 Trait Biosciences, Inc. Systeme und verfahren zur verbesserung der trichombildung und dichte bei cannabis
WO2020014200A1 (en) 2018-07-09 2020-01-16 Volker Berl Stabilized formulations of cannabinoid compositions
WO2020031179A1 (en) 2018-08-06 2020-02-13 Beetlebung Pharma Ltd. Methods for synthesis of cannabinoid compounds
WO2020051371A2 (en) 2018-09-05 2020-03-12 Noramco, Inc. Cannabidiol compositions having modified cannabinoid profiles
US20220009899A1 (en) * 2018-11-14 2022-01-13 Embio Limited Process and compounds for preparation of cannabinoids
WO2020099942A1 (en) * 2018-11-14 2020-05-22 Embio Limited Process and compounds for preparation of cannabinoids
WO2020233502A1 (zh) 2019-05-17 2020-11-26 上海特化医药科技有限公司 大麻二酚类化合物的制备方法
WO2021019536A1 (en) 2019-07-30 2021-02-04 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Methods of controlling cannabinoid synthesis in plants or cells and plants and cells produced thereby
WO2021102428A1 (en) 2019-11-21 2021-05-27 Shinkei Therapeutics, Inc. Cannabidiol and/or cobicistat combination drug therapy
US12391711B2 (en) 2020-01-08 2025-08-19 Chengdu Baiyu Pharmaceutical Co., Ltd. Tetrahydrocannabinol derivatives, preparation method thereof and use thereof
US12545694B2 (en) 2020-01-08 2026-02-10 Chengdu Baiyu Pharmaceutical Co., Ltd. Cannabidiol derivatives, preparation method thereof and use thereof
WO2022115921A1 (en) 2020-12-04 2022-06-09 Cymra Life Sciences Limited Antiinflammatory compositions comprising cannabidiol, delta-9- tetrahydrocannabinol and linalool
US11242328B1 (en) * 2021-02-25 2022-02-08 Acid Neutral Alkaline Laboratory Heterogeneous catalyst and method for preparation of aromatic tricyclic pyrans
WO2022182962A1 (en) * 2021-02-25 2022-09-01 Acid Neutral Alkaline Laboratory Heterogeneous catalyst and method for preparation of aromatic tricyclic pyrans
US12029719B2 (en) 2021-04-16 2024-07-09 Allen Morgan Compounds comprising cannabinoids and other natural ingredients for alieving premenstrual, menstrual and menopausal symptoms
US11352337B1 (en) * 2021-06-02 2022-06-07 Acid Neutral Alkaline Laboratory Zeolite catalyst and method for preparation of aromatic tricyclic pyrans
WO2023006980A1 (en) 2021-07-30 2023-02-02 Cannamedical Pharma Gmbh Transmucosal patch comprising a cannabinoid and/or an opioid
EP4124336A1 (de) 2021-07-30 2023-02-01 Cannamedical Pharma GmbH Transmukosales pflaster mit einem cannabinoid und/oder einem opioid
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
US12458620B2 (en) 2021-11-09 2025-11-04 Cct Sciences, Llc Process for production of essentially pure Δ9-tetrahydrocannabinol
US12103950B2 (en) 2022-01-27 2024-10-01 University Of Connecticut Transgenic plants that overexpress a R2R3-MYB transcription factor gene and methods for producing the same
WO2024160792A1 (en) 2023-01-30 2024-08-08 Cannamedical Pharma Gmbh Improved transmucosal patch comprising a cannabinoid and/or an opioid
WO2024231543A1 (en) 2023-05-10 2024-11-14 Gb Lab Cannabinoid derivatives for treating autism spectrum disorder

Also Published As

Publication number Publication date
DE4100441A1 (de) 1992-07-16
JPH06340650A (ja) 1994-12-13
DE69201959T2 (de) 1995-08-24
EP0494665A1 (de) 1992-07-15
ATE121066T1 (de) 1995-04-15
DK0494665T3 (da) 1995-08-28
ES2071351T3 (es) 1995-06-16
EP0494665B1 (de) 1995-04-12
DE69201959D1 (de) 1995-05-18
JP2637659B2 (ja) 1997-08-06

Similar Documents

Publication Publication Date Title
EP0494665B1 (de) Verfahren zur Herstellung von 6,12-Dihydro-6-hydroxy-cannabidiol und dessen Anwendung zur Herstellung von trans-delta-9-Tetrahydrocannabinol
Fujita et al. On the diterpenoids of Andrographis paniculata: X-ray crystallographic analysis of andrographolide and structure determination of new minor diterpenoids
Unson et al. New polychlorinated amino acid derivatives from the marine sponge Dysidea herbacea
Hoeksema et al. Kalafungin. II. Chemical transformations and the absolute configuration
Kucera et al. Total synthesis of (.+-.)-scopadulcic acid A. An illustration of the utility of palladium catalyzed polyene cyclizations
US5342971A (en) Process for the preparation of dibenzo[b,d]pyrans
US4025516A (en) Process for the preparation of (-)-6a,10a-trans-6a,7,8,10a-tetrahydrodibenzo[b,d]-pyrans
Trifonov et al. Isolation and structure elucidation of three metabolites from Verticillium intertextum: sorbicillin, dihydrosorbicillin and bisvertinoquinol
Omar et al. Phenanthrene lactams from Goniothalamus velutinus
Konował et al. Resolution and absolute configuration of trans (+)-and (−)-6-hydroxymethyl-2-methoxy-5, 6-dihydro-2H-pyrans, substrates for total synthesis of monosaccharides
Narita et al. A novel approach to oxazole-containing diterpenoid synthesis from plant roots: salviamines E and F
Wiley et al. Streptozocin: structure and chemistry
Khandelwal et al. Isolation, structure elucidation and synthesis of 1-deoxyforskolin
Perez et al. An acyclic diterpene and sesquiterpene lactones from Tithonia pedunculata
Muskopf et al. Ring cleavage of cyclohexane-1, 3-diones in the aldol cyclization step of Robinson annelations: a novel mechanism via oxatwistanes and. delta.-lactones
Reese et al. Preparation of medium-sized ring trans-cycloalkene derivatives from halogenocyclopropane intermediates by silver perchlorate-promoted solvolysis
Ruano et al. (Ss)-5-ethoxy-3-p-tolylsulfinylfuran-2 (5H)-ones as chiral dipolarophiles: First asymmetric cycloaddition of diazomethane to vinyl sulfoxides
KOIKE et al. Studies on the Alkaloids of Picrasma quassioides BENNET. VIII.: X-Ray Crystal Structure Analysis of Picrasidine-F
Ayafor et al. Limonoids of Teclea ouabanguiensis
US5231196A (en) Calixarene derivatives and process for the preparation thereof
Liao et al. Intramolecular N-carbamoyliminium ion cyclizations of unactivated alkenes and acetylenes
Chommadov et al. Structure of alkaloid L-5 from Colchicum luteum
CA1122992A (en) Benzocycloheptapyrans, compositions and method of treatment
Beneš et al. Nardiin, a new ent-kaurane diterpenoid from the liverwort Nardia scalaris
Cotterill et al. Studies in the xanthone series. Part 13. Structural and synthetic studies on toxyloxanthone B

Legal Events

Date Code Title Description
AS Assignment

Owner name: HEINRICH MACK NACHF., GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:STOSS, PETER;MERRATH, PETER;REEL/FRAME:006082/0907

Effective date: 19920206

FEPP Fee payment procedure

Free format text: PETITION RELATED TO MAINTENANCE FEES FILED (ORIGINAL EVENT CODE: PMFP); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

REMI Maintenance fee reminder mailed
FP Lapsed due to failure to pay maintenance fee

Effective date: 19970716

SULP Surcharge for late payment
FEPP Fee payment procedure

Free format text: PETITION RELATED TO MAINTENANCE FEES FILED (ORIGINAL EVENT CODE: PMFP); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FEPP Fee payment procedure

Free format text: PETITION RELATED TO MAINTENANCE FEES GRANTED (ORIGINAL EVENT CODE: PMFG); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

PRDP Patent reinstated due to the acceptance of a late maintenance fee

Effective date: 19990108

FPAY Fee payment

Year of fee payment: 4

SULP Surcharge for late payment
FPAY Fee payment

Year of fee payment: 8

LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20050713